Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti-Proliferative
Zhangping Xiao1, Shanshan Song1,2, Deng Chen1
1Department Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Antonius Deusinglaan 1, 9713, AV, Groningen, The Netherlands.
Abstract:
Macrophage migration inhibitory factor (MIF) is involved in protein-protein interactions that play key roles in inflammation and cancer. Current strategies to develop small molecule modulators of MIF functions are mainly restricted to the MIF tautomerase active site. Here, we use this site to develop proteolysis targeting chimera (PROTAC) in order to eliminate MIF from its protein-protein interaction network. We report the first potent MIF-directed PROTAC, denoted MD13, which induced almost complete MIF degradation at low micromolar concentrations with a DC50 around 100 nM in A549 cells. MD13 suppresses the proliferation of A549 cells, which can be explained by deactivation of the MAPK pathway and subsequent induction of cell cycle arrest at the G2/M phase. MD13 also exhibits antiproliferative effect in a 3D tumor spheroid model. In conclusion, we describe the first MIF-directed PROTAC (MD13) as a research tool, which also demonstrates the potential of PROTACs in cancer therapy.
Insights
Researchers developed a novel PROTAC (MD13) to degrade Macrophage migration inhibitory factor (MIF). This new tool effectively reduces cancer cell proliferation by targeting MIF, showing promise for cancer therapy.
Area of Science:
- Biochemistry and Molecular Biology
- Cancer Research
- Drug Discovery
Background:
- Macrophage migration inhibitory factor (MIF) is crucial in inflammation and cancer via protein-protein interactions.
- Existing small molecule modulators primarily target the MIF tautomerase active site.
- Targeting MIF degradation offers a novel therapeutic strategy.
Purpose of the Study:
- To develop the first Macrophage migration inhibitory factor (MIF)-directed proteolysis targeting chimera (PROTAC).
- To investigate the efficacy of this PROTAC in degrading MIF and suppressing cancer cell proliferation.
- To explore the potential of PROTACs as a cancer therapy approach.
Main Methods:
- Design and synthesis of a novel PROTAC targeting MIF.
- Evaluation of MIF degradation using the PROTAC (MD13) in A549 cells.
- Assessment of cell proliferation, MAPK pathway activity, and cell cycle progression.
Main Results:
- The PROTAC MD13 achieved significant MIF degradation at low micromolar concentrations (DC50 ~100 nM) in A549 cells.
- MD13 suppressed A549 cell proliferation by deactivating the MAPK pathway and inducing G2/M cell cycle arrest.
- Antiproliferative effects were confirmed in a 3D tumor spheroid model.
Conclusions:
- MD13 is the first potent Macrophage migration inhibitory factor (MIF)-directed PROTAC, serving as a valuable research tool.
- PROTAC-mediated degradation of MIF demonstrates significant potential for cancer therapy.
- This study highlights a new avenue for developing targeted cancer treatments.
